In order to further guide and regulate sponsors to use real-world data to generate real-world evidences to support drug R&D, the CDE has organized to formulate the Guidance for Real-World Data Used to Generate Real-World Evidences (Interim), which was issued for implementation on April 13 upon review and approval by NMPA.